|
1
|
Labianca R, Nordlinger B, Beretta GD, et
al: Early colon cancer: ESMO Clinical Practice Guidelines for
diagnosis, treatment and follow-up. Ann Oncol. 24:vi64–vi72. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Paquin MC, Leblanc C, Lemieux E, Bian B
and Rivard N: Functional impact of colorectal cancer-associated
mutations in the transcription factor E2F4. Int J Oncol.
43:2015–2022. 2013.PubMed/NCBI
|
|
3
|
Garcia Sanchez J: Colonoscopic polypectomy
and long-term prevention of colorectal cancer deaths. Rev Clin Esp.
212:4082012.(In Spanish).
|
|
4
|
Nystrom M and Mutanen M: Diet and
epigenetics in colon cancer. World J Gastroenterol. 15:257–263.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kim YI: Nutritional epigenetics: impact of
folate deficiency on DNA methylation and colon cancer
susceptibility. J Nutr. 135:2703–2709. 2005.PubMed/NCBI
|
|
6
|
Yamashita K, Dai T, Dai Y, Yamamoto F and
Perucho M: Genetics supersedes epigenetics in colon cancer
phenotype. Cancer Cell. 4:121–131. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Markman B, Javier Ramos F, Capdevila J and
Tabernero J: EGFR and KRAS in colorectal cancer. Adv Clin Chem.
51:71–119. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu S, Xiao X, Lu J, Qian X, Liu B and Feng
J: Colorectal cancer patients with low abundance of KRAS mutation
may benefit from EGFR antibody therapy. PLoS One. 8:e680222013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yokota T: Are KRAS/BRAF mutations potent
prognostic and/or predictive biomarkers in colorectal cancers?
Anticancer Agents Med Chem. 12:163–171. 2012. View Article : Google Scholar :
|
|
10
|
Hamilton SR: BRAF mutation and
microsatellite instability status in colonic and rectal carcinoma:
context really does matter. J Natl Cancer Inst. 105:1075–1077.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tonini G, Imperatori M, Vincenzi B, Frezza
AM and Santini D: Rechallenge therapy and treatment holiday:
different strategies in management of metastatic colorectal cancer.
J Exp Clin Cancer Res. 32:922013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fodde R: The APC gene in colorectal
cancer. Eur J Cancer. 38:867–871. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Woodford-Richens KL, Rowan AJ, Gorman P,
et al: SMAD4 mutations in colorectal cancer probably occur before
chromosomal instability, but after divergence of the microsatellite
instability pathway. Proc Natl Acad Sci USA. 98:9719–9723. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
de Weger VA, Turksma AW, Voorham QJ, et
al: Clinical effects of adjuvant active specific immunotherapy
differ between patients with microsatellitestable and
microsatelliteinstable colon cancer. Clin Cancer Res. 18:882–889.
2012. View Article : Google Scholar
|
|
15
|
Berg M, Danielsen SA, Ahlquist T, et al:
DNA sequence profiles of the colorectal cancer critical gene set
KRAS-BRAF- PIK3CA-PTEN-TP53 related to age at disease onset. PLoS
One. 5:e139782010. View Article : Google Scholar
|
|
16
|
Ilyas M, Tomlinson IP, Rowan A, Pignatelli
M and Bodmer WF: Beta-catenin mutations in cell lines established
from human colorectal cancers. Proc Natl Acad Sci USA.
94:10330–10334. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Georgescu MM: PTEN tumor suppressor
network in PI3K-Akt pathway control. Genes Cancer. 1:1170–1177.
2010. View Article : Google Scholar
|
|
18
|
Song MS, Salmena L and Pandolfi PP: The
functions and regulation of the PTEN tumour suppressor. Nat Rev Mol
Cell Biol. 13:283–296. 2012.PubMed/NCBI
|
|
19
|
Nassif NT, Lobo GP, Wu X, et al: PTEN
mutations are common in sporadic microsatellite stable colorectal
cancer. Oncogene. 23:617–628. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qin Q, Furong W and Baosheng L: Multiple
functions of hypoxia-regulated miR-210 in cancer. J Exp Clin Cancer
Res. 33:502014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y and Taniguchi T: MicroRNAs and DNA
damage response: implications for cancer therapy. Cell Cycle.
12:32–42. 2013. View
Article : Google Scholar :
|
|
22
|
Krishnan K, Steptoe AL, Martin HC, et al:
MicroRNA-182-5p targets a network of genes involved in DNA repair.
RNA. 19:230–242. 2013. View Article : Google Scholar :
|
|
23
|
He YQ, Sheng JQ, Ling XL, et al: Estradiol
regulates miR-135b and mismatch repair gene expressions via
estrogen receptor-beta in colorectal cells. Exp Mol Med.
44:723–732. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ma L, Teruya-Feldstein J and Weinberg RA:
Tumour invasion and metastasis initiated by microRNA-10b in breast
cancer. Nature. 449:682–688. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pencheva N and Tavazoie SF: Control of
metastatic progression by microRNA regulatory networks. Nat Cell
Biol. 15:546–554. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Rottiers V and Näär AM: MicroRNAs in
metabolism and metabolic disorders. Nat Rev Mol Cell Biol.
13:239–250. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dumortier O, Hinault C and Van Obberghen
E: MicroRNAs and metabolism crosstalk in energy homeostasis. Cell
Metab. 18:312–324. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhai H and Ju J: Implications of microRNAs
in colorectal cancer development, diagnosis, prognosis, and
therapeutics. Front Genet. 2:782011. View Article : Google Scholar :
|
|
29
|
Dong Y, Wu WK, Wu CW, Sung JJ, Yu J and Ng
SS: MicroRNA dysregulation in colorectal cancer: a clinical
perspective. Br J Cancer. 104:893–898. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Schetter AJ, Okayama H and Harris CC: The
role of microRNAs in colorectal cancer. Cancer J. 18:244–252. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brunet Vega A, Pericay C, Moya I, et al:
microRNA expression profile in stage III colorectal cancer:
Circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep.
30:320–326. 2013.PubMed/NCBI
|
|
32
|
Khatri R and Subramanian S: MicroRNA-135b
and its circuitry networks as potential therapeutic targets in
colon cancer. Front Oncol. 3:2682013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wu CW, Ng SC, Dong Y, et al:
Identification of microRNA-135b in stool as a potential noninvasive
biomarker for colorectal cancer and adenoma. Clin Cancer Res.
20:2994–3002. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wu W, Wang Z, Yang P, et al: MicroRNA-135b
regulates metastasis suppressor 1 expression and promotes migration
and invasion in colorectal cancer. Mol Cell Biochem. 388:249–259.
2014. View Article : Google Scholar
|
|
35
|
Munding JB, Adai AT, Maghnouj A, et al:
Global microRNA expression profiling of microdissected tissues
identifies miR-135b as a novel biomarker for pancreatic ductal
adenocarcinoma. Int J Cancer. 131:E86–E95. 2012. View Article : Google Scholar
|
|
36
|
Valeri N, Braconi C, Gasparini P, et al:
MicroRNA-135b promotes cancer progression by acting as a downstream
effector of oncogenic pathways in colon cancer. Cancer Cell.
25:469–483. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lee JT, Shan J, Zhong J, et al:
RFP-mediated ubiquitination of PTEN modulates its effect on AKT
activation. Cell Res. 23:552–564. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang X, Trotman LC, Koppie T, et al:
NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell.
128:129–139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang J, Zhang P, Wei Y, et al:
Deubiquitination and stabilization of PTEN by USP13. Nat Cell Biol.
15:1486–1494. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
40
|
Donohoe DR, Collins LB, Wali A, Bigler R,
Sun W and Bultman SJ: The Warburg effect dictates the mechanism of
butyrate-mediated histone acetylation and cell proliferation. Mol
Cell. 48:612–626. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Najafov A and Alessi DR: Uncoupling the
Warburg effect from cancer. Proc Natl Acad Sci USA.
107:19135–19136. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Faltejskova P, Bocanek O, Sachlova M, et
al: Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum:
evidence against their usage as biomarkers in colorectal cancer.
Cancer Biomark. 12:199–204. 2012.PubMed/NCBI
|
|
43
|
Xu XM, Qian JC, Deng ZL, et al: Expression
of miR-21, miR-31, miR-96 and miR-135b is correlated with the
clinical parameters of colorectal cancer. Oncol Lett. 4:339–345.
2012.PubMed/NCBI
|
|
44
|
Zhao Y, Butler EB and Tan M: Targeting
cellular metabolism to improve cancer therapeutics. Cell Death Dis.
4:e5322013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ahmed D, Eide PW, Eilertsen IA, et al:
Epigenetic and genetic features of 24 colon cancer cell lines.
Oncogenesis. 2:e712013. View Article : Google Scholar : PubMed/NCBI
|
